The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.
Pharma, biopharma, and medical device makers should watch out for these perennial problems, which include inadequate ...
What will the industry face or achieve in 2025? These trends will be critical in medical device cybersecurity.
The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks associated with ...
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...
In 2023, the Global Drug Of Abuse Testing Market accounted for USD 6.8 Billion and is expected to reach around USD 11.8 Billion in 2032. Between 2023 and 2032, Lawrence John Prudour +91 91308 55334 ...
The FDA’s Webinar for Manufacturers and Other Interested Parties - The U.S. Food and Drug Administration (FDA) will host a webinar ...
MDR Certification Strengthens Resyca’s Leadership in Soft Mist Drug-Device Combination Products ENSCHEDE, NL / ACCESS ...
In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...
News-Medical speaks with Jordi Labs’ about its recent achievements, alignment with FDA expectations, and strategic ...
Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive report on the, "Medical Device Connectivity ...
The FDA warned the nation about the growing vulnerability of the medical device supply chain and its effects on public health, particularly among pediatric patients, in a Jan. 16 news release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback